A subset of patients with GI cancers harboring <em>NTRK</em> gene fusions had positive responses to selective TRK inhibition with larotrectinib, confirming efficacy of the agent in this group. The results of the confirmatory trial were recently reported the 2020 Gastrointestinal Cancers Symposium.
Jordan D. Berlin, MD
A subset of patients with GI cancers harboringNTRKgene fusions had positive responses to selective TRK inhibition with larotrectinib (Vitrakvi), confirming efficacy of the agent in this group. The results of the confirmatory trial were recently reported the 2020 Gastrointestinal Cancers Symposium.
According to Jordan D. Berlin, MD, who reported the data at the meeting, the overall response rate (ORR) was 43% (95% CI, 18%-71%) and was 50% in patients with colon cancer.1
“We showed that patients with GI cancer are no different than the other cohorts [of patients] with TRK fusion cancers in the way they respond to larotrectinib. Responses are durable. One patient with colon cancer has an ongoing response at 20 months, which is remarkable,” said Berlin, associate director for Clinical Research and director of the phase I clinical trials program at Vanderbilt University in Nashville, Tennessee.
Among responders, the median time to response was 1.8 months (range, 1.7-2.1). The duration of response ranged from 3.5 to more than 14.7 months, and the time on treatment ranged from 0.9 to more than 19.0 months.
At a median follow-up of 19.0 months, the median overall survival was 33.4 months (95% CI, 2.8-36.5) in this subset of patients with TRK fusionpositive GI cancers.
Fourteen patients with TRK fusionpositive GI cancers from a total of 159 enrolled patients treated on either the NCT02122913, SCOUT (NCT02637687), or NAVIGATE (NCT02576431) trials formed the population for this analysis.1All were treated with oral larotrectinib at 100 mg twice daily, until disease progression, withdrawal, or unacceptable toxicity.
The median patient age for the GI cancer subset was 68.0 years (range, 32.0-84.0). Nine of the patients had ≥2 prior lines of therapy. The best response to the most recent therapy was 1 instance of a partial response (PR); 4 others had stable disease (SD). Of the 14 with GI cancer, 8 had colon cancer, 2 had cancer of the bile duct, 2 had pancreatic cancer, 1 had cancer of the appendix, and 1 had liver cancer. Twelve patients hadNTRK1gene­ fusions and 2 had NTRK3gene fusions. Eight patients had stage IV cancer at initial diagnosis. Thirteen patients received prior systemic therapy (7 of whom had 2 prior lines and 2 who had ≥3 prior lines), 12 had surgery, and 1 underwent radiotherapy.
By tumor type, of the 8 patients with colon cancer, 4 had a PR and 4 had SD as their best response; of the 2 patients with pancreatic cancer, 1 had a PR and 1 had SD; of the 2 patients with bile duct cancer, 1 had a PR; and the 1 patient with cancer of the appendix had a PR. Response could not be determined in the 1 patient with liver cancer. Overall, 6 patients had a PR and 6 had SD.
At data cutoff, 4 patients with colon cancer and 1 with pancreatic cancer were alive and without disease progression. Median progression-free survival (PFS) was 5.3 months (95% CI, 2.2-9.0) for the patients with colon cancer (range, 1.5-16.7+).
The 6-month rate of PFS from the start of treatment in all patients with TRK fusion GI cancers was 22%, and the 12-month rate was 11%. The 12-month OS rate was 69%.
Seven of the 8 patients with colon cancer were microsatellite instability (MSI)-high, which is consistent with the literature showing that, “patients with TRK fusion cancer are predominantly identified in the MSI-high subset of patients with colorectal cancer,” said Berlin.
Nine patients experienced grade-3 or -4 treatment-emergent adverse events (TEAEs), with 2 occurrences each of grade 3/4 anemia, bile duct obstruction, hyperbilirubinemia, and sepsis. Two patients had grade-5 TEAEs: 1 with intestinal perforation and 1 with small intestinal obstruction. Seven patients required dose modification (missed, skipped, or delayed dose) due to AEs, but none needed dose reduction.
TRK fusions are generally rare, occurring in <1% of all solid tumors. “It’s a rare cohort, but it’s nice if you have something for that cohort,” he added.
Larotrectinib is a first-in-class, selective inhibitor of TRK approved for the treatment of adult and pediatric patients with TRK fusionpositive cancers.2TRK fusions are oncogenic drivers of various adult and pediatric tumors and arise from rearrangements between neurotrophic tyrosine receptor kinase (NTRK)1,2, or3genes and an unrelated gene.1
In a primary analysis of 55 patients with tumors harboring TRK fusions, larotrectinib exhibited tumor agnostic activity in 17 distinct tumor types with an investigator-assessed ORR of 80%.3That rate was confirmed in the expanded dataset, said Berlin.
“Across cancers, I believe that if patients have good performance status and have the potential to be treated, it’s worthwhile to do next-generation sequencing [NGS]. I think TRK fusions are among the things you should be testing for,” Berlin said. “It’s a rare cohort but because the drug can work, it’s hard to say that you should miss that.”